Humanized antibodies against CEACAM1
US11866509B2 · kind B2 · utility
1Cited by
48References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 18, 2020 |
| Grant date | Jan 9, 2024 |
| Priority date | — |
| Expiry date | Oct 26, 2041 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/70503
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.